Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop ...

At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving ...

Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with ...